Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 6/20 | 0.52 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7321956 | 0.89 | FOLH1 (0.55) | FOLH1PARP1SLC6A4SLC7A5ANPEP | |
| SCHEMBL20222942 | 0.85 | FOLH1 (0.51) | FOLH1PARP1MEP1BSLC6A4SLC7A5 | |
| SCHEMBL28217944 | 0.84 | FOLH1 (0.56) | FOLH1PARP1MEP1BSLC6A4SLC7A5 | |
| SCHEMBL29478099 | 0.84 | SLC7A5 (0.49) | FOLH1SLC7A5ANPEPENPEPEPHX1 | |
| SCHEMBL765921 | 0.84 | FOLH1 (0.61) | FOLH1MEP1BANPEPENPEP | |
| SCHEMBL8098358 | 0.84 | FOLH1 (0.47) | FOLH1SLC7A5ANPEPENPEP | |
| SCHEMBL4054915 | 0.84 | SLC7A5 (0.49) | FOLH1SLC7A5ANPEPENPEPEPHX1 | |
| SCHEMBL9645709 | 0.83 | SLC7A5 (0.43) | FOLH1SLC7A5ANPEPENPEPEPHX1 | |
| SCHEMBL19143670 | 0.83 | SLC7A5 (0.56) | FOLH1PARP1MEP1BSLC6A4SLC7A5 | |
| SCHEMBL14131093 | 0.83 | FOLH1 (0.49) | FOLH1PARP1MEP1BIDH1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11547712-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | UNIVERSITY OF KANSAS (US) | 2022-01-06 | — | — | US | disclosed |
| WO-2021216998-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3400210-B1 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | UNIV PARIS SACLAY (FR) | 2021-09-29 | — | — | EP | disclosed |
| US-11130736-B2 | Human TLR8-selective agonists | UNIVERSITY OF KANSAS (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210238565-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-08-05 | — | — | US | disclosed |
| US-11015180-B2 | Carboxyesterase polypeptides for amide coupling | CODEXIS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-6770650-B2 | CHEMOKINE RECEPTOR (CCR) ANTAGONISTS SUCH AS N-(1(S)-(4-(3,4-DICHLOROBENZYL)PIPERAZIN-1-YLMETHYL)-2-METHYLPROPYL)-4 -METHYLBENZAMIDE DIHYDROCHLORIDE SALT FOR TREATMENT OF ASTHMA | SYNTEX (U.S.A.) LLC | 2004-08-03 | — | — | US | disclosed |
| US-6323223-B1 | CCR-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHODS FOR THEIR USE AND METHODS FOR PREPARING THESE COMPOUNDS. | SYNTEX (U.S.A.) LLC | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | FOLH1 801/4885PARP1 1706/4885MEP1B 642/4885 |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | FOLH1 255/4885PARP1 661/4885MEP1B 394/4885 |
| US-11130736-B2 | Human TLR8-selective agonists | TLR7, TLR8, TLR9 | FOLH1 2711/4885PARP1 1638/4885MEP1B 3041/4885 |
| US-11547712-B2 | Kinase inhibitor compounds and compositions and methods of use | MAP3K20, MAP3K1, PACSIN2 | FOLH1 4501/4885PARP1 2249/4885MEP1B 1213/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | FOLH1 176/4885PARP1 1274/4885MEP1B 330/4885 |
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | TLR7, TLR8, TLR9 | FOLH1 2711/4885PARP1 1638/4885MEP1B 3041/4885 |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | MMP13, MMP9, ADAMTS13 | FOLH1 305/4885PARP1 176/4885MEP1B 349/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | FOLH1 384/4885PARP1 326/4885MEP1B 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.